Radiosensitization of HER2-positive breast cancer cell lines with trastuzumab

49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) -- MAY 31-JUN 04, 2013 -- Chicago, ILWOS: 000335419603139Amer Soc Clin Onco

Comparison of The International Federation of Gynecology and Obstetrics (FIGO) 2018 and 2009 Staging Systems for Operated Cervical Carcinoma

OBJECTIVE The purpose of the study was to compare FIGO 2009 and 2018 uterine cervical carcinoma staging systems in terms of patient distribution and efficacy in predicting treatment outcome in patients treated with surgery and adjuvant radiotherapy (RT)+/-concomitant chemotherapy (CT). METHODS The records of 184 uterine cervical cancer patients treated with post-operative RT/RCT from 2007 to 2017 were retrospectively reviewed. Surgical procedure was in the form of Wertheim surgery in 96 patients (52%) and pelvic lymph node dissection was performed in 32 patients (17.5%). One hundred and sixty-six patients (87.5%) received both external RT and intracavitary brachytherapy, and 23 (12.5%) patients were treated only with external RT. RESULTS The median follow-up time was 61.5 months (range, 8-132 moths). One hundred and fifty-one (82%) patients were alive, and 144 (94%) of these were free of disease at the time of this analysis. The median time for locoregional failure and distant metastasis were 25 months (range, 8-88 months) and 38 months (range, 12-118 months). Stage migration was recorded in 130 patients (70.7%) in our series when the International Federation of Gynecology and Obstetrics (FIGO) 2018 staging system was used. The most remarkable stage migration was detected for Stage I patients. A total of 119 (64.6%) patients with Stage I showed stage migration. Five-year locoregional control, disease-free survival, disease-specific survival, and overall survival rates were 91%, 88%, 91%, and 83%, respectively. CONCLUSION The updated FIGO staging system for invasive cervical cancer incorporates imaging and pathological findings. Our results suggest us that the major improvement of 2018 staging system for uterine cervical carcinoma is that it produced better discrimination in terms of survival outcome in patients with lymph node metastases both pelvic and para-aortic

Postoperative Vaginal Brachytherapy of a Patient with Endometrial Cancer: Case Presentation

###EgeUn###Case: A 39-year-old woman presented with an abnormal postmenopausal vaginal bleeding, and probe curettage was performed for diagnostic purposes. She was diagnosed with endometrial cancer. She underwent total abdominal hysterectomy, bilateral salpingo-oophorectomy, anti pelvic lymph node dissection (TAH+BSO+PPLND). Pathology specimen revealed endometrioid adenocarcinoma sized 2 cm with histologic grade 2. Tumor had halt inner myometrial invasion. Lymphovasculary invasion and lymph node metastases (0/17) were not reported. She was referred to the radiation oncology department tor intracavitary brachytherapy

Evaluation of unusual and highly aggressive variant of endometrium cancer: nonendometrioid endometrium carcinoma of the uterus

WOS: 000416789800009PubMed ID: 26391760Aims: To evaluate the survival and treatment outcomes of patients with nonendometrioid endometrium carcinoma after postoperative radiotherapy. Methods: The records of 94 patients treated with postoperative radiotherapy (RT) between January 2005 and December 2011 were retrospectively reviewed. Postoperative RT was delivered with a dose of 45-50.4 Gy with 1.8 Gy daily fractions and brachytherapy was added to external RT for 62 patients with a dose of 3 x 6 Gy. Median follow-up time was 35 months (range 6-95 months). Results: Median age was 63 years (range 43-83 years) and lymph node metastasis (LNM) was positive in 15 (16.0%) patients. The stage distribution of the patients was as follows: stage I, 58 (61.7%); stage II, 16 (17.0%); stage III, 18 (19.1%); stage IV, 2 (2.2%). Five-year locoregional control (LRC), disease-free survival (DFS), and overall survival (OS) rates were 92.3%, 68.2%, and 78.6%, respectively. In univariable analysis, it was determined that the factors affecting OS rates were stage (p = 0.003), presence of LNM (p = 0.003), and presence of lymphovascular space invasion (LVSI) (p = 0.007); factors affecting DFS rates were stage (p = 0.019), presence of LVSI (p = 0.002), and having LNM (p = 0.049); and the factor affecting LRC rates was tumor size (>5 cm) (p = 0.011). In subgroup analyses, among all stage I patients, the DFS rates were lower for those with histologic grade 3 tumors and more than 1/2 myometrial invasion. Conclusions: Due to its rarity, the prognostic factors and outcomes of nonendometioid endometrium carcinoma are not fully understood. In our analysis, stage, LNM, and presence of LVSI were found to be the most important prognostic factors. In order to tailor the optimal treatment strategy, prospective studies are needed

Expression of Cyclin D1 and Its Relationship to Hormone Receptors and Survival in Breast Cancer

The aim of the present study was to evaluate rate of cyclin D1 expression and examine its relationship to clinicopathological factors and impact on prognosis in breast cancer patients.METHODSTotal of 85 estrogen receptor (ER)-positive breast cancer patients were included. Expression of cyclin D1, ER, progesterone receptor (PR), and Ki-67 were determined using immunohistochemistry evaluation.RESULTSPatients’ median age was 49 years (range: 27–83 years) and cyclin D1 was positive in 90.5% of the patients. Cyclin D1 expression was positively correlated with rate of ER positivity and Ki-67 expression (r=0.4; p<0.0001 and r=0.3; p=0.001, respectively). Five-year disease-free and overall survival (OS) rates were not different between patients with or without cyclin D1 expression (81% vs 79% and 93% vs 87%; p=0.8 and 0.4, respectively). High modified Bloom-Richardson grade (p=0.04), high nuclear grade (p=0.021), and PR negativity (p=0.011) were found to be poor prognostic factors for OS rate in univariate analysis.CONCLUSIONIn this study, cyclin D1 was not found to be prognostic factor; however, it is correlated with ER positivity and Ki-67 expression in breast cancer patient